IG
JAZZ icon

ING Group’s Jazz Pharmaceuticals JAZZ Stock Holding History

ING Group’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.33M Sell
28,214
-23,986
-46% -$4.19M 0.03% 265
2025
Q4 		$8.87M Buy
+52,200
New +$8M 0.05% 214

Other funds holding JAZZ

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

ING Group's JAZZ Position: Q1 2026 in Review

ING Group reduced its Jazz Pharmaceuticals (JAZZ) stake by 46% in Q1 2026, selling an estimated $4.19M and leaving 28,214 shares worth $5.33M. The position accounts for 0.03% of the portfolio, ranked #265.

ING Group first reported a position in JAZZ in Q4 2025 and has held it in 2 quarters since. The position peaked at $8.87M in Q4 2025. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

  • ING Group held 28,214 shares of Jazz Pharmaceuticals worth $5.33M as of Q1 2026.
  • ING Group sold 23,986 Jazz Pharmaceuticals shares in Q1 2026, an estimated $4.19M.
  • Jazz Pharmaceuticals made up 0.03% of ING Group's portfolio in Q1 2026, its #265 holding.
  • ING Group first reported a position in Jazz Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • ING Group's Jazz Pharmaceuticals position peaked at $8.87M in Q4 2025.
  • 570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on ING Group's 13F filing for Q1 2026, filed 11 May 2026.